In Teva Branded Pharm. Prods. R&D v. Amneal Pharms. of N.Y., LLC, the US District Court for the District of New Jersey ordered Teva to delist five patents from the Food and Drug Administration (FDA)’s ...

On June 10, 2024, Judge Stanley R. Chesler of the United States District Court for the District of New Jersey granted the Amneal defendants’ motion for partial judgment on their counterclaims in a ...

When it comes to questioning drug patents, the U.S. Federal Trade Commission (FTC) isn’t backing down. After filing a challenge in November against more than 100 patents in the FDA’s Orange Book—and ...

TEL AVIV, Israel & PARSIPPANY, N.J.--(BUSINESS WIRE)-- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), announced new study findings based on newly ...

Oct 27 (Reuters) - Teva Pharmaceuticals has agreed to pay $35 million and withdraw six patents from a U.S. regulatory list to settle claims that the drugmaker delayed generic competition for its QVAR ...

“There is no dispute that the Inhaler Patents contain no claim for the active ingredient at issue, albuterol sulfate. Amneal contends that the Inhaler Patents do not meet the requirement that they ...

Press releases are posted on Independent.com as a free community service. PARSIPPANY, N.J., Dec. 11, 2024 (GLOBE NEWSWIRE) — Teva Pharmaceuticals, Inc., a U.S ...

Time is running out for patients who use albuterol inhalers to replace those propelled by chlorofluorocarbons (CFCs) with ones that rely on eco-friendly hydrofluoroalkane (HFA). After December 31, ...

PARSIPPANY, N.J., Dec. 11, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (TEVA), announced today the launch of a new patient access ...